BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int 2020;14:677-89. [PMID: 32653991 DOI: 10.1007/s12072-020-10070-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00566-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immunopathol 2022. [PMID: 35415765 DOI: 10.1007/s00281-022-00935-7] [Reference Citation Analysis]
3 Godbole N, Nyholm I, Hukkinen M, Davidson JR, Tyraskis A, Eloranta K, Andersson N, Lohi J, Heikkilä P, Kyrönlahti A, Pihlajoki M, Davenport M, Heikinheimo M, Pakarinen MP. Prognostic and Pathophysiologic Significance of IL-8 (CXCL8) in Biliary Atresia. J Clin Med 2021;10:2705. [PMID: 34207442 DOI: 10.3390/jcm10122705] [Reference Citation Analysis]
4 Yang J, Palmiotti A, Kuipers F. Emerging roles of bile acids in control of intestinal functions. Curr Opin Clin Nutr Metab Care 2021;24:127-33. [PMID: 33075001 DOI: 10.1097/MCO.0000000000000709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Martínez-garcía J, Molina A, González-aseguinolaza G, Weber ND, Smerdou C. Gene Therapy for Acquired and Genetic Cholestasis. Biomedicines 2022;10:1238. [DOI: 10.3390/biomedicines10061238] [Reference Citation Analysis]
6 Grosser G, Müller SF, Kirstgen M, Döring B, Geyer J. Substrate Specificities and Inhibition Pattern of the Solute Carrier Family 10 Members NTCP, ASBT and SOAT. Front Mol Biosci 2021;8:689757. [PMID: 34079822 DOI: 10.3389/fmolb.2021.689757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
8 Ayoub MD, Kamath BM. Alagille Syndrome: Diagnostic Challenges and Advances in Management. Diagnostics (Basel) 2020;10:E907. [PMID: 33172025 DOI: 10.3390/diagnostics10110907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
10 Ibrahim SH, Kamath BM, Loomes KM, Karpen SJ. Cholestatic liver diseases of genetic etiology: Advances and controversies. Hepatology 2022;75:1627-46. [PMID: 35229330 DOI: 10.1002/hep.32437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, Lacaille F, Lachaux A, Sturm E, Setchell KDR, Kennedy C, Dorenbaum A, Steinmetz J, Desai NK, Wardle AJ, Garner W, Vig P, Jaecklin T, Sokal EM, Jacquemin E. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet 2021;398:1581-92. [PMID: 34755627 DOI: 10.1016/S0140-6736(21)01256-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Aneja A, Scott E, Kohli R. Advances in management of end stage liver disease in children. Med J Armed Forces India 2021;77:129-37. [PMID: 33867627 DOI: 10.1016/j.mjafi.2021.03.001] [Reference Citation Analysis]
13 Luoto TT, Pakarinen MP. Evolving management of paediatric portal hypertension. Arch Dis Child 2021:archdischild-2020-319600. [PMID: 33692083 DOI: 10.1136/archdischild-2020-319600] [Reference Citation Analysis]
14 Li C, Yu S, Li X, Cao Y, Li M, Ji G, Zhang L. Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice. Front Pharmacol 2022;13:833414. [PMID: 35721143 DOI: 10.3389/fphar.2022.833414] [Reference Citation Analysis]
15 Zhang B, Kuipers F, de Boer JF, Kuivenhoven JA. Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles. J Clin Med 2021;11:4. [PMID: 35011746 DOI: 10.3390/jcm11010004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Henkel SAF, Salgado CM, Reyes-Mugica M, Soltys KA, Strauss K, Mazariegos GV, Squires RH, McKiernan PJ, Zhang X, Squires JE. Long-term liver transplant outcomes for progressive familial intrahepatic cholestasis type 1: The Pittsburgh experience. Pediatr Transplant 2021;:e14108. [PMID: 34339082 DOI: 10.1111/petr.14108] [Reference Citation Analysis]
17 Deeks ED. Odevixibat: First Approval. Drugs 2021;81:1781-6. [PMID: 34499340 DOI: 10.1007/s40265-021-01594-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Shneider BL, Kamath BM, Magee JC, Goodrich NP, Loomes KM, Ye W, Spino C, Alonso EM, Molleston JP, Bezerra JA, Wang KS, Karpen SJ, Horslen SP, Guthery SL, Rosenthal P, Squires RH, Sokol RJ; Childhood Liver Disease Research Network (ChiLDReN). Use of funded multicenter prospective longitudinal databases to inform clinical trials in rare diseases-Examination of cholestatic liver disease in Alagille syndrome. Hepatol Commun 2022. [PMID: 35506349 DOI: 10.1002/hep4.1970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Nguyen HPA, Ren J, Butler M, Li H, Qazi S, Sadiq K, Dao HT, Holterman A. Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia. Pediatr Surg Int 2022. [PMID: 35391541 DOI: 10.1007/s00383-022-05115-0] [Reference Citation Analysis]
20 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]